Standard BioTools

Standard BioTools OCF Growth YoY

The Year-over-Year Operating Cash Flow Growth of Standard BioTools (LAB) as of Nov 5, 2026 is 48.17 %. In the previous year, Year-over-Year Operating Cash Flow Growth was -231.40 % — a change of -120.82% (higher).

OCF Growth YoY

48.17 %

YoY

-120.82%

Last updated:

Year-over-Year Operating Cash Flow Growth of Standard BioTools is 2025 48.17 % . Year-over-Year Operating Cash Flow Growth of Standard BioTools was 2024 -231.40 % . It decreases by -120.82% higher compared to the previous year.

The Standard BioTools OCF Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Growth YoY
Date
OCF Growth YoY
Jan 1, 2018
-4.58 USD
Jan 1, 2019
-39.72 USD
Jan 1, 2020
56.21 USD
Jan 1, 2021
-185.79 USD
Jan 1, 2022
-102.83 USD
Jan 1, 2023
51.56 USD
Jan 1, 2024
-231.40 USD
Jan 1, 2025
48.17 USD
The Standard BioTools OCF Growth YoY history
YEAROCF Growth YoYYoY
48.17 %-120.82%
-231.40 %-548.76%
51.56 %-150.14%
-102.83 %-44.65%
-185.79 %-430.51%
56.21 %-241.54%
-39.72 %+767.72%
-4.58 %-111.93%
38.37 %-402.39%
-12.69 %-76.23%
-53.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Year-over-Year Operating Cash Flow Growth of Standard BioTools is 48.17 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Operating Cash Flow Growth Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

OCF growth measures the percentage change in operating cash flow. Growing OCF indicates improving cash generation from core operations.

To evaluate Year-over-Year Operating Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Operating Cash Flow Growth.

Year-over-Year Operating Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Operating Cash Flow Growth's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Standard BioTools

All Key Metrics — Standard BioTools